Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Japanese H3 rocket fails during launch of navigation satellite (video) - 2How does Spotify Wrapped calculate your listening age? What your number says about you.
- 3Best Wellness Tracker Keep You On target
- 4Figure out How to Ascertain the Restitution Time frame for Your Sunlight based chargers
- 5Manual for Vegetarian Protein Powder
- Yemen's Houthis ready to join Iran war if needed, raising new shipping risk
- The 20 Most sultry Style of the Time
- Space debris: will it take a catastrophe for nations to take the issue seriously?
- Grasping Wrongdoings and Crimes: A Correlation
- Mechanical Sidekick d: A Survey of \Elements and Execution d\ Cell phone
- Italy now recognizes the crime of femicide and punishes it with life in prison
- I served on the expert committee that advised the government on new dietary guidelines – most of our recommendations were ignored
- Wonderful Sea shores All over the Planet
- Qantas and Virgin Australia Ban Power Bank Usage on Flights Following Safety Incidents
